In this issue:
Tamoxifen for long-term chemoprevention
Fulvestrant in advanced breast cancer
Lapatinib in ErbB2 positive advanced or metastatic breast cancer
Addition of paclitaxel to dose dense EC vs CEF or AC-T
Breast cancer recurrence and mortality: Impact of LHRH agonists
Boost radiation following breast-conserving treatment
Micrometastases in the sentinel node: take it or leave it?
Dietary fat reduction and breast cancer outcomes
Sharply reduced breast cancer incidence in the United States
BCIRG 006: Trastuzumab for HER-2 positive early breast cancer
HER-2 expression and response to adjuvant chemotherapy
ER/PgR expression, HER2 status and breast cancer recurrence
Download PDF